Gilead Sciences, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious diseases. Its portfolio is led by antiviral medicines for HIV and viral hepatitis, as well as treatments for emerging viral infections. The company also has a growing oncology franchise, including cell therapies through its Kite subsidiary and antibody-drug conjugates.
Founded in 1987 and headquartered in Foster City, California, Gilead conducts research, clinical development, and large-scale production through a global network. Its work spans small‑molecule and biologic modalities, with an emphasis on advancing therapies with significant public health impact. The company collaborates with academic, biotech, and manufacturing partners worldwide to support R&D, clinical trials, and supply chain needs.